These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9566806)

  • 1. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans.
    Amass L; Bickel WK; Crean JP; Blake J; Higgins ST
    Psychopharmacology (Berl); 1998 Apr; 136(3):217-25. PubMed ID: 9566806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternate-day dosing during buprenorphine treatment of opioid dependence.
    Amass L; Bickel WK; Higgins ST; Badger GJ
    Life Sci; 1994; 54(17):1215-28. PubMed ID: 8164503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens.
    Petry NM; Bickel WK; Badger GJ
    Addiction; 2001 Jun; 96(6):823-34. PubMed ID: 11399214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.
    Petry NM; Bickel WK; Badger GJ
    Clin Pharmacol Ther; 1999 Sep; 66(3):306-14. PubMed ID: 10511067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible?
    Petry NM; Bickel WK; Badger GJ
    Addiction; 2000 Jul; 95(7):1069-77. PubMed ID: 10962771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.
    Amass L; Kamien JB; Mikulich SK
    Drug Alcohol Depend; 2000 Feb; 58(1-2):143-52. PubMed ID: 10669065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients.
    Eissenberg T; Johnson RE; Bigelow GE; Walsh SL; Liebson IA; Strain EC; Stitzer ML
    Drug Alcohol Depend; 1997 Apr; 45(1-2):81-91. PubMed ID: 9179510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients.
    Bickel WK; Amass L; Crean JP; Badger GJ
    Psychopharmacology (Berl); 1999 Sep; 146(2):111-8. PubMed ID: 10525745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing.
    Johnson RE; Eissenberg T; Stitzer ML; Strain EC; Liebson IA; Bigelow GE
    Drug Alcohol Depend; 1995 Nov; 40(1):27-35. PubMed ID: 8746921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.
    Marsch LA; Bickel WK; Badger GJ; Jacobs EA
    Drug Alcohol Depend; 2005 Feb; 77(2):195-204. PubMed ID: 15664721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.
    Tompkins DA; Smith MT; Mintzer MZ; Campbell CM; Strain EC
    J Pharmacol Exp Ther; 2014 Feb; 348(2):217-26. PubMed ID: 24227768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans.
    Amass L; Kamien JB; Mikulich SK
    Drug Alcohol Depend; 2001 Jan; 61(2):173-81. PubMed ID: 11137282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days.
    Gross A; Jacobs EA; Petry NM; Badger GJ; Bickel WK
    Drug Alcohol Depend; 2001 Sep; 64(1):111-6. PubMed ID: 11470347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.
    Ahmadi J; Jahromi MS; Ehsaei Z
    Trials; 2018 Aug; 19(1):462. PubMed ID: 30157924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients.
    Mattick RP; Ali R; White JM; O'Brien S; Wolk S; Danz C
    Addiction; 2003 Apr; 98(4):441-52. PubMed ID: 12653814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence.
    Pérez de los Cobos J; Martin S; Etcheberrigaray A; Trujols J; Batlle F; Tejero A; Queraltó JM; Casas M
    Drug Alcohol Depend; 2000 Jun; 59(3):223-33. PubMed ID: 10812283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.